Primary pulmonary adenocarcinoma in a 16-year-old boy - a five-year follow-up

被引：3

作者：

Mareng, Ane Stillits ^{[1
]}

Langer, Seppo W. ^{[2
]}

Bodtger, Uffe ^{[1
,3
]}

机构：

[1] Naestved Hosp, Dept Resp Med, 61 Ringstedgade, DK-4700 Naestved, Denmark

[2] Copenhagen Univ Hosp, Rigshosp, Dept Oncol, Head Thorac & Neuroendocrine Unit, Copenhagen, Denmark

[3] Univ Southern Denmark, Inst Reg Hlth Res, Odense, Denmark

来源：

EUROPEAN CLINICAL RESPIRATORY JOURNAL | 2016年 / 3卷

关键词：

non-small cell lung cancer; metastasis; survival; adolescent; diagnosis;

D O I：

10.3402/ecrj.v3.32633

中图分类号：

R56 [呼吸系及胸部疾病];

学科分类号：

摘要：

Primary pulmonary adenocarcinoma in children or adolescents is a rare disease, and as such, there are no randomised studies on lung cancer for this age group. Treatment choice is extrapolated from studies in adults (mean age of participants: 60 years). We present the 5-year follow-up of a 16-year-old boy who presented with metastatic primary pulmonary adenocarcinoma (T3N3M1a) and was treated aggressively, including radiation therapy for local and distant recurrence. He had complete remission, had completed his education, was employed full-time, and suffered only from mild side effects to treatment.

引用

页数：3

共 24 条

[1] Cisplatin-versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: An individual patient data meta-analysis
Ardizzoni, Andrea
Boni, Luca
Tiseo, Marcello
Fossella, Frank V.
Schiller, Joan H.
Paesmans, Marianne
Radosavljevic, Davorin
Paccagnella, Adriano
Zatloukal, Petr
Mazzanti, Paola
Bisset, Donald
Rosell, Rafael
[J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2007, 99 (11) : 847 - 857
[2] Induction Chemotherapy With Triweekly Docetaxel and Cisplatin Followed by Concomitant Chemoradiotherapy With or Without Surgery in Stage III Non-Small-Cell Lung Cancer: A Phase II Study
Aydiner, Adnan
Sen, Fatma
Saglam, Esra Kaytan
Oral, Ethem Nezih
Eralp, Yesim
Tas, Faruk
Toker, Alper
Dilege, Sukru
[J]. CLINICAL LUNG CANCER, 2011, 12 (05) : 286 - 292
[3] Efficacy and safety of erlotinib versus chemotherapy in second-line treatment of patients with advanced, non-small-cell lung cancer with poor prognosis (TITAN): a randomised multicentre, open-label, phase 3 study
Ciuleanu, Tudor
Stelmakh, Lilia
Cicenas, Saulius
Miliauskas, Skaidrius
Grigorescu, Alexandru Calin
Hillenbach, Carina
Johannsdottir, Hrefna Kristin
Klughammer, Barbara
Esteban Gonzalez, Emilio
[J]. LANCET ONCOLOGY, 2012, 13 (03) : 300 - 308
[4] Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study
Ciuleanu, Tudor
Brodowicz, Thomas
Zielinski, Christoph
Kim, Joo Hang
Krzakowski, Maciej
Laack, Eckart
Wu, Yi-Long
Bover, Isabel
Begbie, Stephen
Tzekova, Valentina
Cucevic, Branka
Pereira, Jose Rodrigues
Yang, Sung Hyun
Madhavan, Jayaprakash
Sugarman, Katherine P.
Peterson, Patrick
John, William J.
Krejcy, Kurt
Belani, Chandra P.
[J]. LANCET, 2009, 374 (9699) : 1432 - 1440
[5] Non-Small Cell Lung Cancer, Version 6.2015 Featured Updates to the NCCN Guidelines
Ettinger, David S.
Wood, Douglas E.
Akerley, Wallace
Bazhenova, Lyudmila A.
Borghaei, Hossein
Camidge, David Ross
Cheney, Richard T.
Chirieac, Lucian R.
D'Amico, Thomas A.
Demmy, Todd L.
Dilling, Thomas J.
Dobelbower, M. Chris
Govindan, Ramaswamy
Grannis, Frederic W., Jr.
Horn, Leora
Jahan, Thierry M.
Komaki, Ritsuko
Krug, Lee M.
Lackner, Rudy P.
Lanuti, Michael
Lilenbaum, Rogerio
Lin, Jules
Loo, Billy W., Jr.
Martins, Renato
Otterson, Gregory A.
Patel, Jyoti D.
Pisters, Katherine M.
Reckamp, Karen
Riely, Gregory J.
Rohren, Eric
Schild, Steven E.
Shapiro, Theresa A.
Swanson, Scott J.
Tauer, Kurt
Yang, Stephen C.
Gregory, Kristina
Hughes, Miranda
[J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2015, 13 (05): : 515 - 524
[6] Erlotinib versus docetaxel as second-line treatment of patients with advanced non-small-cell lung cancer and wild-type EGFR tumours (TAILOR): a randomised controlled trial
Garassino, Marina Chiara
Martelli, Olga
Broggini, Massimo
Farina, Gabriella
Veronese, Silvio
Rulli, Eliana
Bianchi, Filippo
Bettini, Anna
Longo, Flavia
Moscetti, Luca
Tomirotti, Maurizio
Marabese, Mirko
Ganzinelli, Monica
Lauricella, Calogero
Labianca, Roberto
Floriani, Irene
Giaccone, Giuseppe
Torri, Valter
Scanni, Alberto
Marsoni, Silvia
[J]. LANCET ONCOLOGY, 2013, 14 (10) : 981 - 988
[7] CHILDHOOD PRIMARY PULMONARY NEOPLASMS
HANCOCK, BJ
DILORENZO, M
YOUSSEF, S
YAZBECK, S
MARCOTTE, JE
COLLIN, PP
[J]. JOURNAL OF PEDIATRIC SURGERY, 1993, 28 (09) : 1133 - 1136
[8] Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy
Hanna, N
Shepherd, FA
Fossella, FV
Pereira, JR
De Marinis, F
von Pawel, J
Gatzemeier, U
Tsao, TCY
Pless, M
Muller, T
Lim, HL
Desch, C
Szondy, K
Gervais, R
Shaharyar
Manegold, C
Paul, S
Paoletti, P
Einhorn, L
Bunn, PA
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (09) : 1589 - 1597
[9] PRIMARY PULMONARY NEOPLASMS OF CHILDHOOD - A REVIEW
HARTMAN, GE
SHOCHAT, SJ
[J]. ANNALS OF THORACIC SURGERY, 1983, 36 (01) : 108 - 119
[10] Vinorelbine/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity
Helbekkmo, N.
Sundstrom, S. H.
Aasebo, U.
Brunsvig, P. Fr
von Plessen, C.
Hjelde, H. H.
Garpestad, O. K.
Bailey, A.
Bremnes, R. M.
[J]. BRITISH JOURNAL OF CANCER, 2007, 97 (03) : 283 - 289

← 1 2 3 →